M B Youdim

Summary

Affiliation: Technion-Israel Institute of Technology
Country: Israel

Publications

  1. ncbi request reprint The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice
    M B H Youdim
    Eve Topf and US National Parkinson Foundation, Centers of Excellence for Neurodegenerative Diseases Research, Technion Rappaport Family Faculty of Medicine, Haifa, Israel
    J Neural Transm 114:205-9. 2007
  2. doi request reprint Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs
    Orly Weinreb
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion Faculty of Medicine, Haifa, 31096, Israel
    Neurotherapeutics 6:163-74. 2009
  3. pmc A molecular signature in blood identifies early Parkinson's disease
    Leonid Molochnikov
    Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Mol Neurodegener 7:26. 2012
  4. pmc Physiological and pathological aspects of Abeta in iron homeostasis via 5'UTR in the APP mRNA and the therapeutic use of iron-chelators
    Yael Avramovich-Tirosh
    Department of Pharmacology, Eve Topf and USA NPF Centers of Excellence, Technion Faculty of Medicine, Haifa, Israel
    BMC Neurosci 9:S2. 2008
  5. ncbi request reprint cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells
    Orly Weinreb
    Department of Pharmacology, Technion Faculty of Medicine, P O B 9697, 31096 Haifa, Israel
    FASEB J 17:935-7. 2003
  6. ncbi request reprint Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus
    M B H Youdim
    Eve Topf and USA National Parkinson Foundation, Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion Faculty of Medicine, Haifa, Israel
    Neurotox Res 14:45-56. 2008
  7. doi request reprint Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?
    Moussa B H Youdim
    Technion Rappaport Family Faculty of Medicine, Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases, Haifa, Israel
    Parkinsonism Relat Disord 13:S281-91. 2007
  8. ncbi request reprint Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil
    Moussa B H Youdim
    Technion Rappaport Family Faculty of Medicine, Eve Topf and NPF Centers for Neurodegenerative Diseases Department of Pharmacology Haifa, Israel
    Neurotox Res 10:181-92. 2006
  9. ncbi request reprint Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326
    Moussa B H Youdim
    Department of Pharmacology, Technion Faculty of Medicine, Haifa, Israel
    Ann N Y Acad Sci 993:378-86; discussion 387-93. 2003
  10. ncbi request reprint The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline
    Moussa B H Youdim
    Eve Topf and National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research, Department of Pharmacology, Technion Faculty of Medicine, Efron Street, P O Box 9697, Haifa 31096, Israel
    Biochem Pharmacol 66:1635-41. 2003

Collaborators

Detail Information

Publications98

  1. ncbi request reprint The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice
    M B H Youdim
    Eve Topf and US National Parkinson Foundation, Centers of Excellence for Neurodegenerative Diseases Research, Technion Rappaport Family Faculty of Medicine, Haifa, Israel
    J Neural Transm 114:205-9. 2007
    ..The results indicate that for prevention of MPTP-induced dopamine depletion and dopamine neurodegeneration, iron rather than copper chelation may be more effective and specific...
  2. doi request reprint Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs
    Orly Weinreb
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion Faculty of Medicine, Haifa, 31096, Israel
    Neurotherapeutics 6:163-74. 2009
    ..Altogether, these scientific findings make these multifunctional compounds potentially valuable drugs for the treatment of Alzheimer's disease...
  3. pmc A molecular signature in blood identifies early Parkinson's disease
    Leonid Molochnikov
    Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Mol Neurodegener 7:26. 2012
    ..We aim to assess whether a gene signature could be detected in blood from early/mild PD patients that could support the diagnosis of early PD, focusing on genes found particularly altered in the substantia nigra of sporadic PD...
  4. pmc Physiological and pathological aspects of Abeta in iron homeostasis via 5'UTR in the APP mRNA and the therapeutic use of iron-chelators
    Yael Avramovich-Tirosh
    Department of Pharmacology, Eve Topf and USA NPF Centers of Excellence, Technion Faculty of Medicine, Haifa, Israel
    BMC Neurosci 9:S2. 2008
    ....
  5. ncbi request reprint cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells
    Orly Weinreb
    Department of Pharmacology, Technion Faculty of Medicine, P O B 9697, 31096 Haifa, Israel
    FASEB J 17:935-7. 2003
    ..Our results provide for the first time new insights into the molecular events involved in the dose-dependent neuroprotective and neurotoxic activities of catechols and indole amine compounds...
  6. ncbi request reprint Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus
    M B H Youdim
    Eve Topf and USA National Parkinson Foundation, Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion Faculty of Medicine, Haifa, Israel
    Neurotox Res 14:45-56. 2008
    ..In animal models of iron deficiency it is apparent that dopaminergic interaction with the opiate system and cholinergic neurotransmission may be defective...
  7. doi request reprint Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?
    Moussa B H Youdim
    Technion Rappaport Family Faculty of Medicine, Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases, Haifa, Israel
    Parkinsonism Relat Disord 13:S281-91. 2007
    ....
  8. ncbi request reprint Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil
    Moussa B H Youdim
    Technion Rappaport Family Faculty of Medicine, Eve Topf and NPF Centers for Neurodegenerative Diseases Department of Pharmacology Haifa, Israel
    Neurotox Res 10:181-92. 2006
    ..These findings indicate that the dual actions of the anti-apoptotic-neuroprotective activity and the ability to modulate APP processing, could make ladostigil a potentially valuable drug for the treatment of Alzheimer's disease...
  9. ncbi request reprint Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326
    Moussa B H Youdim
    Department of Pharmacology, Technion Faculty of Medicine, Haifa, Israel
    Ann N Y Acad Sci 993:378-86; discussion 387-93. 2003
    ..These data suggest a novel pharmacological mechanism, whereby these ChE inhibitors regulate the secretary processes of APP via activation of the MAP kinase pathway...
  10. ncbi request reprint The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline
    Moussa B H Youdim
    Eve Topf and National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research, Department of Pharmacology, Technion Faculty of Medicine, Efron Street, P O Box 9697, Haifa 31096, Israel
    Biochem Pharmacol 66:1635-41. 2003
    ....
  11. ncbi request reprint Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation
    Moussa B H Youdim
    Department of Pharmacology, Bruce Rappaport Faculty of Medicine Technion, Eve Topf and National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research, Efron St, PO Box 9697, Haifa 31096, Israel
    Neurotoxicology 25:243-50. 2004
    ..Pharmacologically it has limited tyramine potentiation, very similar to moclobemide and being a MAO-AB inhibitor it has the antidepressant, anti-Parkinson and anti-Alzheimer activities in the respective models used to develop such drugs...
  12. ncbi request reprint CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases
    M B H Youdim
    Technion Rappaport Family Faculty of Medicine, Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases, Haifa, Israel
    J Neural Transm 112:519-37. 2005
    ..Also, the simplification of the therapeutic regimen for individuals with AD who have difficulty with compliance is important...
  13. ncbi request reprint Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition
    Moussa B H Youdim
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Technion Faculty of Medicine, 31096 Haifa, Israel
    J Neurosci Res 79:172-9. 2005
    ....
  14. ncbi request reprint Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28
    Moussa B H Youdim
    Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research, and Department of Pharmacology, Technion Rappaport Faculty of Medicine, Haifa, Israel
    Ann N Y Acad Sci 1012:306-25. 2004
    ....
  15. ncbi request reprint Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax
    Moussa B H Youdim
    Eve Topf and National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research, Faculty of Medicine, Technion, Efron Street, P O Box 9697, Haifa 31096, Israel
    Neuropharmacology 46:1130-40. 2004
    ..The neuroprotective action of lithium in this model of Parkinson's disease has been attributed to its antiapoptotic activity which among other factors includes induction of Bcl-2 and reduction of Bax...
  16. ncbi request reprint Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders
    Moussa B H Youdim
    Eve Topf and US National Parkinson Foundation, Centers of Excellence for Neurodegenerative Diseases Research, Technion Rappaport Faculty of Medicine and Department of Pharmacology, Haifa 31096, Israel
    Trends Pharmacol Sci 26:27-35. 2005
    ..These bi- or multi-functional compounds might provide greater symptomatic efficacy, and better utility as potential neuroprotective disease-modifying drugs...
  17. ncbi request reprint Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases
    Moussa B H Youdim
    Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Technion Faculty of Medicine, Efron St, PO Box 9697, Haifa 31096, Israel
    Mech Ageing Dev 126:317-26. 2005
    ..These compounds have been shown to have iron chelating and monoamine oxidase A and B selective brain inhibitory and neuroprotective-antiapoptotic actions...
  18. ncbi request reprint A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease
    Moussa B H Youdim
    Department of Pharmacology, Technion Bruce Rappaport Faculty of Medicine, Eve Topf and NPF Neurodegenerative Diseases Centers, Rappaport Family Research Institute, Haifa, Israel
    Neurology 63:S32-5. 2004
  19. ncbi request reprint Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases
    M B H Youdim
    Eve Topf and National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research, and Department of Pharmacology, Technion Rapapport Faculty of Medicine, Haifa, Israel
    J Neural Transm 111:1455-71. 2004
    ..We have now developed several of these compounds with neuroprotective, MAO inhibitory and iron chelating properties from our prototype iron chelators, VK-28 possessing propargylamine moiety of our anti-parkinson drug, rasagiline...
  20. ncbi request reprint The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo
    M B Youdim
    Technion Faculty of Medicine, Eve Topf and NPF Neurodegenerative Disease Centers, Efron Street, Bat Galim, Haifa, Israel
    Ann N Y Acad Sci 939:450-8. 2001
    ....
  21. ncbi request reprint The therapeutic potential of monoamine oxidase inhibitors
    Moussa B H Youdim
    Technion Rappaport Family Faculty of Medicine, Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases
    Nat Rev Neurosci 7:295-309. 2006
    ..We evaluate these arguments in the light of what we know, and still have to learn, of the structure, function and genetics of the monoamine oxidases and the disparate actions of their inhibitors...
  22. pmc Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
    Moussa B H Youdim
    Department of Pharmacology and Technion Bruce Rappaport Faculty of Medicine, Eve Topf and NPF Centers of Excellence for Neurodegenerative Diseases Research and Teaching, Haifa, Israel
    Br J Pharmacol 147:S287-96. 2006
    ..These aspects of MAO and its inhibition and some indication of how this important area of pharmacology and therapeutics might develop in the future are summarized in this review...
  23. ncbi request reprint Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]
    M B Youdim
    Eve Topf and National Parkinson Foundation Centers for Neurodegenerative Diseases Research, Department of Pharmacology, Technion Faculty of Medicine, Haifa, Israel
    Cell Mol Neurobiol 21:555-73. 2001
    ..It is quite likely that the induction of Bcl-2 and activation of PKC by rasagiline and TV3326 is closely linked to the anti-apoptotic action of these drugs and their ability to process APP by activation of alpha-secretase...
  24. ncbi request reprint The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators
    M B Youdim
    Technion, Faculty of Medicine, Eve Topf, Haifa, Israel
    Ann N Y Acad Sci 890:7-25. 1999
    ....
  25. doi request reprint M30, a brain permeable multitarget neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models
    Moussa B H Youdim
    Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases, Technion Rappaport Family Faculty of Medicine, Haifa, Israel
    Parkinsonism Relat Disord 18:S151-4. 2012
    ..These findings indicates that brain-permeable M30 has neurorestorative activity, which may clearly be of clinical importance for the treatment of PD...
  26. ncbi request reprint Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline
    Moussa B H Youdim
    Eve Topf and NPF Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Technion Rappaport Faculty of Medicine, Haifa, Israel
    Drugs Today (Barc) 41:369-91. 2005
    ..Long-term studies are required to evaluate the drug's disease-modifying prospects in Parkinson's and Alzheimer's diseases...
  27. ncbi request reprint Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline
    Moussa B H Youdim
    Technion Faculty of Medicine, Eve Topf and NPF Centers, 31096, Haifa, Israel
    Mech Ageing Dev 123:1081-6. 2002
    ..Thus MAO inhibition by propargylamines is not a pre-requisite for neuroprotection. Rather, propargylamines have some intrinsic neuroprotective property whose mechanism of action requires further elucidation...
  28. ncbi request reprint The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30
    Moussa B H Youdim
    Eve Topf Centres of Excellence for Neurodegenerative Diseases Research, Technion Rappaport Family Faculty of Medicine and Department of Pharmacology, Haifa, Israel
    Curr Alzheimer Res 3:541-50. 2006
    ..These series of drugs have the ability of regulating and processing APP (amyloid precursor protein) and reducing Abeta peptide, since APP is a metaloprotein, with an iron responsive element 5d'UTR similar to transferring and ferritin...
  29. ncbi request reprint Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss
    E Grunblatt
    Eve Topf National Parkinson s Foundation Center for Neurodegenerative Diseases, Technion, Israel
    J Neurochem 77:146-56. 2001
    ....
  30. ncbi request reprint Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine
    Orit Bar-Am
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research, and Department of Pharmacology, Rappaport Family Research Institute, Technion Faculty of Medicine, Haifa, Israel
    FASEB J 19:1899-901. 2005
    ..These results indicate that both rasagiline and propargylamine possess neurorescue activity, associated with regulation of Bcl-2 family proteins, neurotrophic factors, and APP metabolism...
  31. ncbi request reprint Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration
    Y Levites
    Eve Topf, Technion-Faculty of Medicine, Haifa, Israel
    J Neurochem 78:1073-82. 2001
    ....
  32. ncbi request reprint Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate
    Silvia Mandel
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology and Rappaport Family Research Institute, Technion Faculty of Medicine, Haifa, 31096, Israel
    J Mol Neurosci 24:401-16. 2004
    ..This study supports the notion that a combination of iron chelation and antioxidant therapy, as emphasized on several occasions, might be a significant approach to neuroprotection in PD and other neurodegenerative diseases...
  33. doi request reprint Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30
    Shunit Gal
    Department of Pharmacology, Technion Rappaport Family Faculty of Medicine, Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases, Efron St, P O Box 9697, Haifa, 31096, Israel
    Neurotox Res 17:15-27. 2010
    ..6% of control) cell count in the SNpc. Finally, M30 was shown to decrease mitosis, thus providing additional protection. These findings suggest that brain-permeable M30 may clearly be of clinical importance for the treatment of PD...
  34. ncbi request reprint A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate
    Orly Weinreb
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion Faculty of Medicine, Haifa 31096, Israel
    Free Radic Biol Med 43:546-56. 2007
    ..Thus, the present study sheds some light on the antioxidative-iron chelating activities of EGCG underlying its neuroprotective/neurorescue mechanism of action, further suggesting a potential neurodegenerative-modifying effect for EGCG...
  35. ncbi request reprint Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism
    Yotam Sagi
    Eve Topf and USA National Parkinson Foundation, Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Technion Rappaport Faculty of Medicine, POB 9697, 31096 Haifa, Israel
    Neurobiol Dis 25:35-44. 2007
    ..It is interesting to determine whether a similar effect is seen in parkinsonian patients after long-term treatment with rasagiline...
  36. ncbi request reprint Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor
    Yotam Sagi
    Eve Topf and USA National Parkinson Foundation, Centers of Excellence for Neurodegenerative Diseases Research, Technion Faculty of Medicine, Haifa, Israel
    J Neurochem 86:290-7. 2003
    ..This may explain its antidepressant-like activity, resembling that of moclobemide in the forced-swim test in rats...
  37. ncbi request reprint Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline
    Merav Yogev-Falach
    Technion Faculty of Medicine, Eve Topf and NPF Centers for Neurodegenerative Diseases Department of Pharmacology Haifa, Israel
    FASEB J 16:1674-6. 2002
    ..These data suggest a novel pharmacological mechanism whereby these ChE inhibitors regulate the secretory processes of APP via activation of the MAP kinase pathway...
  38. ncbi request reprint Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases
    Orly Weinreb
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion Faculty of Medicine, 31096 Haifa, Israel
    J Nutr Biochem 15:506-16. 2004
    ..In particular, literature on the putative novel neuroprotective mechanism of the major green tea polyphenol, (-)-epigallocatechin-3-gallate, are examined and discussed in this review...
  39. pmc Effects of the glycine prodrug milacemide (2-N-pentylaminoacetamide) on catecholamine secretion from isolated adrenal medulla chromaffin cells
    G Yadid
    Department of Pharmacology, Faculty of Medicine, Technion Israel Institute of Technology, Haifa
    Br J Pharmacol 104:760-4. 1991
    ..6. It is apparent that release of catecholamines by glycine is mediated by its uptake into the cells since [3H]-glycine uptake and catecholamine release showed a highly significant correlation (r = 0.96)...
  40. ncbi request reprint Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs
    M Weinstock
    Department of Pharmacology, Hebrew University Faculty of Medicine, Jerusalem, Israel
    Ann N Y Acad Sci 939:148-61. 2001
    ..The latter does not result from ChE inhibition. It is associated with the presence of the propargyl group, since it occurs with other propargylamines that do not inhibit MAO, but not with drugs that inhibit only ChE...
  41. ncbi request reprint A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing
    Merav Yogev-Falach
    Eve Topf Center of Excellence for Neurodegenerative Diseases Research and Dept of Pharmacology, Rappaport Family Research Institute, Technion Faculty of Medicine, 31096 Haifa, Israel
    FASEB J 20:2177-9. 2006
    ..Similar to ladostigil, its S-isomer, TV3279, which is a ChE inhibitor but lacks MAO inhibitory activity, exerted neuroprotective properties and regulated APP processing, indicating that these effects are independent of MAO inhibition...
  42. ncbi request reprint Green tea polyphenol (-) -epigallocatechin-3-gallate promotes the rapid protein kinase C- and proteasome-mediated degradation of Bad: implications for neuroprotection
    Limor Kalfon
    Eve Topf Center for Neurodegenerative Diseases, and Department of Pharmacology, Faculty of Medicine, Technion, Haifa, Israel
    J Neurochem 100:992-1002. 2007
    ..6-fold). The present study reveals a novel pathway in the neuroprotective mechanism of the action of EGCG, which involves a rapid PKC-mediated degradation of Bad by the proteasome...
  43. pmc The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats
    Yotam Sagi
    Eve Topf and U S A National Parkinson Foundation, Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Technion Rappaport Faculty of Medicine, Haifa, Israel
    Br J Pharmacol 146:553-60. 2005
    ....
  44. doi request reprint The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats
    Orit Bar-Am
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Faculty of Medicine, Technion, Haifa, 31096, Israel
    J Mol Neurosci 37:135-45. 2009
    ....
  45. ncbi request reprint The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing
    Merav Yogev-Falach
    Technion Faculty of Medicine, Eve Topf and NPF Centers for Neurodegenerative Diseases, Department of Pharmacology, Haifa, Israel
    FASEB J 17:2325-7. 2003
    ....
  46. ncbi request reprint Gene and protein expression profiles of anti- and pro-apoptotic actions of dopamine, R-apomorphine, green tea polyphenol (-)-epigallocatechine-3-gallate, and melatonin
    Orly Weinreb
    Eve Topf, Haifa, Israel
    Ann N Y Acad Sci 993:351-61; discussion 387-93. 2003
    ..We have shown that DA, R-APO, EGCG, and melatonin exhibit similar gene expression and protein profiles...
  47. ncbi request reprint Involvement of protein kinase C activation and cell survival/ cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action
    Yona Levites
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research, Dept of Pharmacology, Technion Faculty of Medicine, 31096 Haifa, Israel
    J Biol Chem 277:30574-80. 2002
    ..These results suggest that the neuroprotective mechanism of EGCG against oxidative stress-induced cell death includes stimulation of PKC and modulation of cell survival/cell cycle genes...
  48. ncbi request reprint The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons
    D Ben-Shachar
    Rappaport Family Research Institute, Faculty of Medicine, Technion, Haifa, Israel
    J Neurochem 56:1441-4. 1991
    ..The ability of iron chelators to retard dopaminergic neurodegeneration in the substantia nigra may indicate a new therapeutic strategy in the treatment of Parkinson's disease...
  49. ncbi request reprint Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine
    E Grunblatt
    Technion Faculty of Medicine, Eve Topf and US National Parkinson s Foundation Centers for Neurodegenerative Diseases, Department of Pharmacology, Haifa, Israel
    J Neurochem 78:1-12. 2001
    ..The attenuation of these gene changes by R-apomorphine, an iron chelator-radical scavenger drug, supports our previous findings in vivo where R-apomorphine was neuroprotective...
  50. ncbi request reprint The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection
    Orly Weinreb
    Eve Topf Center of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Faculty of Medicine, Technion, Haifa, Israel
    Antioxid Redox Signal 9:169-79. 2007
    ..These results support the hypothesis that OS and mitochondrial dysfunction may play a pivotal role in aging and age-associated neurodegenerative diseases, and can serve as potential clinical targets for future therapy...
  51. ncbi request reprint Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members
    Orly Weinreb
    Eve Topf and Rappaport Family Research Institute, Technion Faculty of Medicine, Haifa, Israel
    FASEB J 18:1471-3. 2004
    ..Furthermore, these studies have established that PKC- and Bcl-2-dependent neuroprotective activity of rasagiline is dependent on its propargyl moiety, because propargylamine had similar effects with the same potency...
  52. ncbi request reprint Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate
    Yona Levites
    Eve Topf and USA National Parkinson Foundation, Centers of Excellence for Neurodegenerative Diseases Research, Technion Faculty of Medicine, Haifa, Israel
    FASEB J 17:952-4. 2003
    ..Thus, EGCG has protective effects against Abeta-induced neurotoxicity and regulates secretory processing of non-amyloidogenic APP via PKC pathway...
  53. ncbi request reprint Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators
    Tamar Amit
    Eve Topf Center of Excellence for Neurodegenerative Diseases Research, Department of Pharmacology, Faculty of Medicine, Technion, Faculty of Medicine, Haifa, Israel
    FASEB J 22:1296-305. 2008
    ..A similar approach in drug design is being investigated for treatment of cancer, AIDS, cardiovascular diseases, and depression...
  54. doi request reprint The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage
    Danit Mechlovich
    Eve Topf Center of Excellence for Neurodegenerative Diseases Research and Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion, Israel
    J Pharmacol Exp Ther 333:874-82. 2010
    ....
  55. ncbi request reprint Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo
    Orit Bar-Am
    Technion Faculty of Medicine, Eve Topf and NPF Centers for Neurodegenerative Diseases, Department of Pharmacology, Haifa, Israel
    J Neurochem 89:1119-25. 2004
    ..The activation and induction of PKC and MARCKS by these drugs may have a crucial role not only in their neuroprotective activity, but also in their ability to affect neuronal plasticity and spatial learning processes...
  56. ncbi request reprint Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway
    Silvia A Mandel
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research, Technion Faculty of Medicine, Haifa, Israel
    Neurosignals 14:46-60. 2005
    ..In particular, their transitional metal (iron and copper) chelating property and inhibition of oxidative stress...
  57. ncbi request reprint The neuroprotective effect of Activin A and B: implication for neurodegenerative diseases
    Lana Kupershmidt
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion Faculty of Medicine, Haifa, Israel
    J Neurochem 103:962-71. 2007
    ..These results indicate that both Activin-A and -B share the potential to induce neuroprotective activity and thus may have positive impact on aging and neurodegenerative diseases to retard the accelerated rate of neuronal degeneration...
  58. ncbi request reprint Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease
    Yael Avramovich-Tirosh
    Eve Topf Centers of Excellence, Technion Rappaport Family Faculty of Medicine and Department of Pharmacology, Haifa, Israel
    J Neurochem 100:490-502. 2007
    ....
  59. ncbi request reprint Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures
    Yona Levites
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research, Technion Faculty of Medicine, Haifa, Israel
    Biochem Pharmacol 63:21-9. 2002
    ..Brain penetrating property of polyphenols may make such compounds an important class of drugs for treatment of neurodegenerative diseases...
  60. doi request reprint Metallocorroles as cytoprotective agents against oxidative and nitrative stress in cellular models of neurodegeneration
    Lana Kupershmidt
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Faculty of Medicine, Rappaport Family Research Institute, Technion Israel Institute of Technology, Haifa, 31096, Israel
    J Neurochem 113:363-73. 2010
    ..These results highlight the large potential of corrole complexes as novel agents for therapeutic approaches in degenerative disorders of the central and peripheral nervous systems, where oxidative and nitrative stresses are involved...
  61. ncbi request reprint Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway
    Orly Weinreb
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research, Department of Pharmacology, Rappaport Family Research Institute, Technion Faculty of Medicine, Haifa, Israel
    Ann N Y Acad Sci 1053:348-55. 2005
    ..These results have led us to develop several multifunctional neuroprotective drugs containing the propargyl moiety and iron-chelating property for the treatment and/or prevention of neurodegenerative diseases...
  62. pmc A sporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1A
    Tali Fishman-Jacob
    Eve Topf and National Parkinson Foundation Centers for Neurodegenerative Diseases and the Department of Molecular Pharmacology, Faculty of Medicine, Technion, 31096 Haifa, Israel
    J Biol Chem 284:32835-45. 2009
    ..In summary, this new model has reproduced to a significant extent the molecular alterations described in sporadic PD at the cellular level, implicating Skp1 as a potential modifier in sporadic PD neurodegeneration...
  63. ncbi request reprint Preferential release of epinephrine by glycine from adrenal chromaffin cells
    G Yadid
    Technion Bruce Rappaport Faculty of Medicine, Department of Pharmacology, Haifa, Israel
    Eur J Pharmacol 221:389-91. 1992
    ..This differential effect could be of physiological importance considering our recent demonstration of a functional high-affinity chloride-gated glycine receptor on adrenal chromaffin cells...
  64. ncbi request reprint Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro
    Orit Bar-Am
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion Faculty of Medicine, Haifa, Israel
    J Neurochem 103:500-8. 2007
    ....
  65. doi request reprint limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30
    Shunit Gal
    Department of Pharmacology, Technion Rappaport Family Faculty of Medicine, Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases, Efron St, PO Box 9697, Haifa 31096, Israel
    Neurotox Res 18:143-50. 2010
    ....
  66. ncbi request reprint Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG
    Yael Avramovich-Tirosh
    Eve Topf and USA NPF Centers of Excellence, Technion Rappaport Family Faculty of Medicine and Department of Pharmacology, Haifa, Israel
    Curr Alzheimer Res 4:403-11. 2007
    ....
  67. ncbi request reprint Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion
    Shunit Gal
    Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases, Technion Rappaport Family Faculty of Medicine and Department of Pharmacology, Haifa, Israel
    J Neurochem 95:79-88. 2005
    ....
  68. ncbi request reprint Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70
    Silvia Mandel
    Eve Topf and USA National Parkinson Foundation Centers of Excellence and Department of Pharmacology, Family Research Institute, Technion Rappaport Family Faculty of Medicine, Haifa, Israel
    Ann N Y Acad Sci 1053:356-75. 2005
    ....
  69. ncbi request reprint Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases
    Silvia Mandel
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Technion Faculty of Medicine, Haifa, Israel
    J Neurochem 88:1555-69. 2004
    ....
  70. ncbi request reprint Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs
    Silvia Mandel
    Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Technion Rappaport Faculty of Medicine, PO Box 9697, Haifa 31096, Israel
    Trends Pharmacol Sci 24:184-91. 2003
    ....
  71. ncbi request reprint Green tea polyphenol (-)-epigallocatechin-3-gallate protects rat PC12 cells from apoptosis induced by serum withdrawal independent of P13-Akt pathway
    Silvia Mandel
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research, Technion Faculty of Medicine, Haifa 31096, Israel
    Neurotox Res 5:419-24. 2003
    ..1 and 1 microM) significantly protects rat pheochromocytoma PC12 cells from apoptosis induced by serum support withdrawal, suggesting that EGCG may play a role in the growth of PC12 cells, where it stimulates survival-promoting pathways...
  72. ncbi request reprint Genes and oxidative stress in parkinsonism: cDNA microarray studies
    Silvia Mandel
    Eve Topf and U S National Parkinson s Foundation Centers of Excellence for Neurodegenerative Diseases, Bruce Rappaport Family Research Institute, Department of Pharmacology, Faculty of Medicine, Technion, Haifa, Israel
    Adv Neurol 91:123-32. 2003
  73. ncbi request reprint Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases
    Silvia Mandel
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology and Rappaport Family Research Institute, Technion Faculty of Medicine, Haifa 31096, Israel
    Free Radic Biol Med 37:304-17. 2004
    ..As a consequence these compounds are receiving significant attention as therapeutic cytoprotective agents for the treatment of neurodegenerative and other diseases...
  74. ncbi request reprint The neurochemical basis of cognitive deficits induced by brain iron deficiency: involvement of dopamine-opiate system
    M B Youdim
    Technion Faculty of Medicine, Eve Topf and National Parkinson Foundation US, Centers for Neurodegenerative Diseases Research, Department of Pharmacology, Haifa, Israel
    Cell Mol Biol (Noisy-le-grand) 46:491-500. 2000
    ....
  75. doi request reprint Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases
    Silvia A Mandel
    Eve Topf Center for Neurodegenerative Diseases Research and Department of Pharmacology, Faculty of Medicine, Technion, Haifa, Israel
    CNS Neurosci Ther 14:352-65. 2008
    ..In the current article, we review the literature on the impact of the multimodal activities of green tea polyphenols and their neuroprotective effect on AD and PD...
  76. ncbi request reprint Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours
    John P M Finberg
    Pharmacology Department, Rappaport Family Faculty of Medicine, Technion, POB 9649, Haifa, Israel
    Neuropharmacology 43:1110-8. 2002
    ..Rasagiline does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit MAO-B but not MAO-A...
  77. doi request reprint Modeling sporadic Parkinson's disease by silencing the ubiquitin E3 ligase component, SKP1A
    Silvia A Mandel
    Eve Topf Center for Neurodegenerative Diseases Research and Department of Molecular Pharmacology, Faculty of Medicine Technion, Haifa, Israel
    Parkinsonism Relat Disord 15:S148-51. 2009
    ....
  78. ncbi request reprint The neuroprotective mechanism of action of the multimodal drug ladostigil
    Orly Weinreb
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion Faculty of Medicine, Haifa, 31096, Israel
    Front Biosci 13:5131-7. 2008
    ..Altogether, these scientific findings make ladostigil a potentially valuable drug for the treatment of AD...
  79. doi request reprint The application of proteomics for studying the neurorescue activity of the polyphenol (-)-epigallocatechin-3-gallate
    Orly Weinreb
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion Faculty of Medicine, Haifa 31096, Israel
    Arch Biochem Biophys 476:152-60. 2008
    ....
  80. ncbi request reprint Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline
    Orit Bar Am
    Eve Topf and US National Parkinson Foundation Center of Excellence for Neurodegenerative Diseases Research, Technion Faculty of Medicine, Efron St PO Box 9697, Haifa 31096, Israel
    Neurosci Lett 355:169-72. 2004
    ..These findings may have implication for the possible disease modifying action of rasagiline in treatment of Parkinson's disease...
  81. doi request reprint Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD
    Silvia A Mandel
    Eve Topf Center for Neurodegenerative Diseases Research and Department of Pharmacology, Faculty of Medicine, Technion, Haifa, Israel
    Parkinsonism Relat Disord 13:S242-7. 2007
    ..The uncovered signatures may serve as future predictive biomarkers for early PD diagnosis, disease progression and drug development...
  82. ncbi request reprint Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders
    Silvia Mandel
    Eve Topf, Haifa, Israel
    Mol Nutr Food Res 50:229-34. 2006
    ....
  83. ncbi request reprint Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG)
    Silvia A Mandel
    Eve Topf Center for Neurodegenerative Diseases Research and Department of Pharmacology, Faculty of Medicine, Technion, Haifa, Israel
    J Alzheimers Dis 15:211-22. 2008
    ..This review provides a detailed overview on the multimodal activities of green tea polyphenols with emphasis on their iron chelating, neurorescue/neuroregenerative and mitochondrial stabilization action...
  84. doi request reprint Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain
    Orly Weinreb
    Department of Pharmacology, Technion Faculty of Medicine, Rappaport Family Research Institute, Eve Topf Centers of Excellence for Neurodegenerative Diseases Research, Haifa, Israel
    J Neural Transm 116:1457-72. 2009
    ....
  85. doi request reprint Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities
    Orly Weinreb
    Eve Topf Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion Faculty of Medicine, Haifa, Israel
    Antioxid Redox Signal 13:919-49. 2010
    ..This review discusses two interrelated approaches concerning therapy targets in neurodegeneration, sharing in common the implementation of iron chelation activity: antioxidation and HIF-1-pathway activation...
  86. ncbi request reprint Targeting multiple neurodegenerative diseases etiologies with multimodal-acting green tea catechins
    Silvia A Mandel
    Eve Topf Center for Neurodegenerative Diseases Research and Department of Pharmacology, Faculty of Medicine, Technion, Haifa, Israel
    J Nutr 138:1578S-1583S. 2008
    ..This article elaborates on the multimodal activities of green tea polyphenols with emphasis on their recently described neurorescue/neuroregenerative and mitochondrial stabilization actions...
  87. ncbi request reprint Shedding of growth hormone-binding protein is inhibited by hydroxamic acid-based protease inhibitors: proposed mechanism of activation of growth hormone-binding protein secretase
    T Amit
    Department of Pharmacology, Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
    J Endocrinol 169:397-407. 2001
    ..In the long run, specific inhibitors of these processes could be applied in the regulation of GHBP levels and, thus, of GH availability and/or activity...
  88. ncbi request reprint Autoradiographic localization of strychnine-sensitive glycine receptor in bovine adrenal medulla
    G Yadid
    Department of Pharmacology, Technion Bruce Rappaport Faculty of Medicine, Haifa, Israel
    Neurochem Res 18:1051-5. 1993
    ..This difference supports biochemical evidence for glycine transport into medulla cells and glycine receptor sites on the chromaffin cell membrane...
  89. ncbi request reprint An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells
    Yukihiro Akao
    Gifu International Institute of Biotechnology, Mitake, Kani gun, Gifu, Japan
    Neurosci Lett 326:105-8. 2002
    ..Enhanced expression of bcl-2 family indicates the ability of rasagiline to adjust the apoptotic threshold and protect degenerating neurons in PD...
  90. ncbi request reprint Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan
    Yukihiro Akao
    Gifu International Institute of Biotechnology and Department of Brain Sciences, Mitake, Gifu, Japan
    J Neurochem 82:913-23. 2002
    ..Altogether, mitochondrial PT plays a key role both in NM(R)Sal-induced cell death and the neuroprotective effect of rasagiline...
  91. ncbi request reprint Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor
    Wakako Maruyama
    Laboratory of Biochemistry and Metabolism, Department of Basic Gerontology, National Institute for Longevity Sciences, Obu, Aichi, Japan
    Neurosci Lett 341:233-6. 2003
    ..This resulted in stabilization of the mitochondrial membrane potential, the collapse of which initiates the apoptotic cascade...
  92. ncbi request reprint Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases
    Cornelis J Van der Schyf
    Texas Tech University Health Sciences Center, Department of Pharmaceutical Sciences, School of Pharmacy, 1300 Coulter Drive, Amarillo, TX 79106, USA
    Expert Opin Investig Drugs 15:873-86. 2006
    ..This review offers a synopsis of therapeutic strategies and novel investigative drugs developed in the authors' own and other laboratories that modulate multiple disease targets associated with neurodegenerative diseases...
  93. doi request reprint Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration
    Wen Zhu
    Department of Neurology, The 1st Affiliated Hospital of Sun Yat sen University, Guangzhou, China
    J Neurochem 105:1970-8. 2008
    ..Our study indicates that compared with selegiline, rasagiline is more potent in protecting neurodegeneration induced by UPS impairment and may, therefore, exert disease-modifying effects in PD...
  94. ncbi request reprint Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases
    Hailin Zheng
    Department of Organic Chemistry and Neurobiology, The Weizmann Institute of Science, Rehovot 76100, Israel
    Bioorg Med Chem 13:773-83. 2005
    ..EPR studies suggested that Chelator 9 also act as radical scavenger to directly scavenge hydroxyl radical...
  95. ncbi request reprint Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives
    Silvia Mandel
    Eve Topf and NPF Centers of Excellence for Neurodegenerative Diseases Research, Israel
    Brain Res Brain Res Rev 48:379-87. 2005
    ..The neuroprotective activity of propargylamine has led us to develop novel bifunctional neuroprotective iron-chelating MAO-inhibiting drugs possessing propargyl moiety for the treatment of other neurodegenerative diseases...
  96. ncbi request reprint Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition
    Hailin Zheng
    Department of Organic Chemistry and Neurobiology, The Weizmann Institute of Science, Rehovot, Israel
    J Neurochem 95:68-78. 2005
    ..2 microM. The data suggest that M30 and HLA20 might serve as leads in developing drugs with multifunctional activities for the treatment of various neurodegenerative disorders...
  97. ncbi request reprint Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons
    Hailin Zheng
    Department of Organic Chemistry, The Weizmann Institute of Science, Herzl St, Rehovot 76100, Israel
    Biochem Pharmacol 70:1642-52. 2005
    ..These results suggest that M10 deserves further investigation as a potential agent for the treatment of neurodegenerative disorders such as AD and PD...
  98. ncbi request reprint Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators
    Wen Zhu
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    FASEB J 21:3835-44. 2007
    ..Furthermore, M30, a derivative of VK-28 and neuroprotective agent rasagiline, may serve as a better neuroprotective therapy for PD...